Please assess the completion status of the following clinical trial:

Trial Title: Home-Based Programs for Improving Sleep in Cancer Survivors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Prior diagnosis of cancer~* At least 2 months and ≤ 24 months since completed curative-intent treatment (chemotherapy, surgery, and/or radiotherapy)~  * Ongoing hormonal therapy (i.e., tamoxifen, aromatase inhibitors, casodex)~ * Concurrent trastuzumab and maintenance rituximab allowed~* Sleep difficulty defined as self report of sleep latency of ≥ 30 minutes on 3 out of 7 nights in a week and wishing therapeutic intervention, and/or self report of waking up after first falling asleep and not being able to fall back asleep for ≥ 30 minutes on 3 out of 7 nights in a week~* No history of diagnosis of primary insomnia (patient medical record, defined by having had behavioral, cognitive, or pharmacologic treatment) for \> 30 consecutive days in the year before cancer diagnosis~* No active cancer (i.e., not considered no evidence of disease)~* No concurrent CNS malignancy~* No history of diagnosed sleep disorder (i.e., obstructive sleep apnea, restless legs, or periodic leg movement disorder)~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Availability of a CD player and head or earphones~* Ability to complete questionnaires~* No uncontrolled chronic pain (i.e., pain score of ≥ 4 on Numeric Analogue Sleep and Pain Scale)~* No diagnosis of major depression disorder, acute anxiety disorder, or schizophrenia per medical record~* No hot flashes that interrupt sleep~* Not working overnight hours and unable to change schedule~* No emotional, psychological, or physical state that, according to physician and/or study personnel evaluation, would preclude adherence to daily home intervention implementation~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 4 days since prior corticosteroid, including inhaled steroids, of any dose for \> 2 days~* No prior experience with guided imagery or cognitive behavioral therapy for insomnia~* No concurrent new herbal therapies~  * Stable dose of daily herbal supplements started ≥ 8 weeks before study intervention allowed~ * Herbal teas or herbs in various drink products allowed~* No concurrent treatment with variable doses of any of the following:~  * Antidepressants~ * Anxiolytics~ * Pain medication (not including over the counter ad anti-inflammatory pain relievers)~* Pharmacologic treatment for sleep/wake disturbances is allowed, but must be used for 4 weeks before study entry, and can be used daily or intermittently

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Home-based sleep intervention with Device #1 (Type: EXPERIMENTAL): Participants listen to a pre-recorded mp3 device #1 before retiring to sleep. Only patients in Arm A will have assigned bed and wake times based on their baseline diary.
- Arm B: Home-based sleep intervention with Device #2 (Type: ACTIVE_COMPARATOR): Participants will listen to a pre-recorded mp3 device #2 before retiring to sleep. At the end of the study, participants assigned to pre-recorded mp3 device #2 will be offered pre-recorded mp3 device #1 for their own use.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues